Last updated: February 20, 2026
What is the drug associated with NDC 70700-0116?
NDC 70700-0116 corresponds to Rimegepant Oral Tablet, 75 mg, developed by Pfizer. It is approved by the FDA for the acute and preventive treatment of migraines.
Market Overview
Therapeutic Area and Market Demand
The migraine treatment market focuses on a broad segment of patients experiencing episodic or chronic migraines. Our key points:
- Incidence: Approximately 1 in 7 Americans suffer from migraines (CDC, 2020).
- Market size: The U.S. migraine market was valued around $2.6 billion in 2022, with projected compounded annual growth rate (CAGR) of 4.3% through 2027 (Grand View Research, 2022).
- Competitive landscape: Includes triptans, gepants (like rimegepant and ubrogepant), ditans, and CGRP monoclonal antibodies.
- Key competitors: Ubrogepant (Nurtec ODT), lasmiditan (Emgality), and CGRP antibodies.
Regulatory Status and Approvals
- FDA Approval Timeline:
- Rimegepant for acute migraine: October 2020.
- Rimegepant for preventive migraine: March 2022.
- Other Markets:
- Approved in Japan (2021) and EMA (European Medicines Agency, 2022).
Prescriber and Patient Access
Data indicates increasing adoption driven by:
- Efficacy compared to triptans.
- Favorable tolerability profile.
- Expanding insurance coverage.
Market Projections
Revenue Forecasts
- 2022: Approximate revenue of $500 million in the U.S.
- 2023-2028: Growth to $1.2 billion by 2028, driven by:
- Expanded indications.
- Increased uptake amongst both acute and preventive users.
- US pricing adjustments reflecting market dynamics.
Pricing Strategies
- Current Price Points:
- Rimegepant (Pfizer): approximately $35-$45 per 75 mg tablet.
- Ubrogepant: comparable pricing, approx. $34 per tablet.
- Insurance Coverage:
- Common rebates and pharmacy benefit management (PBM) negotiations influence net prices.
- Co-pay support programs enhance patient access.
Outlook on Market Share
- Pfizer's Rimegepant is projected to hold approximately 35-40% of the gepant segment by 2028.
- Competition from Ubrogepant, with similar efficacy and pricing, remains robust.
- Expanding indications and patient population increases are anticipated to shift market share favorably for Pfizer.
Price Projections (2023–2028)
| Year |
Estimated Wholesale Price (per 75 mg tablet) |
Projected Market Share |
Estimated Revenue (USD, millions) |
| 2023 |
$40 |
25% |
$550 |
| 2024 |
$38 |
30% |
$700 |
| 2025 |
$36 |
35% |
$850 |
| 2026 |
$34 |
37% |
$1,050 |
| 2027 |
$34 |
39% |
$1,200 |
| 2028 |
$33 |
40% |
$1,250 |
Pricing assumes modest reductions due to rebates and negotiations.
Key Influencers
- Generic competition: Entry of low-cost generics could depress prices by 10-15% after patent expiry (~2030).
- Regulatory shifts: Expanded indications could increase eligible patient numbers by 15-20%.
- Reimbursement policies: Adjustments in insurance coverage could either constrain or expand revenue.
Summary
- The global migraine market is expanding, with a focus on CGRP receptor antagonists like rimegepant.
- Pfizer's Rimegepant holds a substantial share in fast-growing segments.
- Price points will likely stabilize around current levels with gradual declines due to rebate strategies.
- Revenue is expected to reach approximately $1.2 billion globally by 2028, contingent upon competitive dynamics and market expansion.
Key Takeaways
- Rimegepant's market is driven by escalating migraine prevalence and expanding approvals.
- Pricing remains stable with slight reductions due to rebate and insurance negotiations.
- Competitive pressures from similar gepants and potential generics influence future pricing.
- Market share is expected to grow slowly, reaching roughly 40% of the gepant segment by 2028.
- Long-term revenue is projected to approximate $1.2 billion globally, assuming stable market conditions.
FAQs
Q1: How does the pricing of Rimegepant compare to its main competitors?
It is comparable, around $35-$45 per tablet, with slight variations based on negotiated rebates and insurance arrangements.
Q2: What are the primary factors that could affect future price projections?
Market entry of generics, regulatory changes expanding indications, and shifts in reimbursement policies.
Q3: How much market share can Rimegepant expect in the migraine segment?
Forecasts suggest around 35-40% of the gepant market by 2028.
Q4: Are there geographic variations in market penetration?
Yes. The U.S. dominates market share, but European and Asian markets are expanding with newer approvals and evolving reimbursement landscapes.
Q5: What is the impact of upcoming patent expiry or generic entry?
Potential price erosion of 10-15%, with significant revenue impact unless offset by increased market penetration or new indications.
References
[1] Grand View Research. (2022). Migraine therapeutics market size, share & trends analysis.
[2] CDC. (2020). Migraine prevalence report.
[3] U.S. FDA. (2020). Rimegepant approval documents.
[4] Pfizer. (2022). Rimegepant prescribing information.
